Fabtech Tech Targets ₹600 Crore Revenue for FY27 with 30% Order Book Growth

Market snapshot: Fabtech Technologies has reaffirmed its long-term growth trajectory, projecting a significant scale-up in revenue and profitability by FY27 and FY28. The company is leveraging its robust biopharma infrastructure pipeline to drive a 30% expansion in its order book while maintaining high contribution margins.

Summary: Fabtech Tech maintains its ₹600 crore revenue target for FY27 and projects PAT to hit 14% by FY28, supported by 30% YoY order book growth.

Data Snapshot

• Revenue Target (FY27): ₹530 Cr to ₹600 Cr
• PAT Guidance (FY28): 12% to 14%
• EBITDA Margin Target: 13% to 14%
• Order Book Growth: 25% to 30% YoY
• Contribution Margin: ~45%

What's Changed

• Current revenue of ~₹431 Cr (FY26) is set to expand to a peak of ₹600 Cr by FY27.
• The order book growth guidance of 30% accelerates from previous execution cycles.
• Targeted PAT margins of 9-11% (immediate) rising to 12-14% (FY28) signal structural efficiency gains.

Key Takeaways

• Management confirms consistency in high-growth revenue targets despite global macro volatility.
• Emphasis on 45% contribution margins highlights strong pricing power in specialized cleanroom engineering.
• Order book visibility remains high with a projected 30% annual growth rate.

SAHI Perspective

Fabtech's ability to maintain guidance for ₹600 Cr revenue—a nearly 40% jump from FY26 levels—suggests a massive execution pipeline in the Middle East and African pharmaceutical sectors. The shift toward a 14% PAT margin indicates that the company is successfully transitioning from a pure-play engineering firm to a high-value infrastructure platform with integrated services.

Market Implications

The reaffirmed guidance provides strong earnings visibility for the next 24 months. Sectorally, the expansion of biopharma infrastructure in the GCC region (Oman/Saudi) is a major tailwind. For capital allocation, the consistent revenue targets may lead to re-rating as the company scales toward the ₹600 crore milestone.

Trading Signals

Market Bias: Bullish

Reaffirmed ₹600 Cr revenue target and 30% order growth guidance provide a clear visibility of 20%+ earnings CAGR, supported by high 45% contribution margins.

Overweight: Biopharma Infrastructure, Pharma Engineering, Capital Goods

Underweight: High-debt Infrastructure

Trigger Factors:

• Order inflow announcements from MENA region
• Quarterly margin progression toward 14% EBITDA
• Working capital cycle efficiency

Time Horizon: Medium-term (3-12 months)

Industry Context

The global life sciences infrastructure market is seeing a localized shift, particularly in the Middle East, as nations seek pharmaceutical self-reliance. Fabtech’s integrated 'turnkey' model allows it to capture higher value compared to fragmented competitors.

Key Risks to Watch

• Execution delays in large-scale international projects.
• Fluctuations in raw material costs affecting the 45% contribution margin.
• Currency volatility in emerging markets (Africa/GCC).

Recent Developments

On April 28, 2026, Fabtech reported FY26 total income of ₹431.33 Cr and a PAT of ₹38.36 Cr. The company also recently approved the establishment of a subsidiary in Oman to bolster its local execution strategy in the GCC region.

Closing Insight

Fabtech's strategic roadmap from ₹431 Cr to ₹600 Cr revenue relies on aggressive order book expansion and superior margin management, positioning it as a key beneficiary of the global pharma capex cycle.

FAQs

How does Fabtech plan to reach the ₹600 Cr revenue target by FY27?

The target is backed by a current order book of over ₹900 crore and a projected 25-30% YoY growth in new orders, specifically targeting the pharmaceutical and renewable energy sectors.

What is the significance of the 45% contribution margin target?

A 45% contribution margin is significantly higher than general engineering peers, indicating strong competitive moats in specialized cleanroom and HVAC solutions for biopharma.

Why is the FY28 PAT guidance higher than the current internal target?

The jump to 12-14% PAT in FY28 from the current 9-11% range is expected to be driven by operating leverage, scale benefits, and the increasing share of higher-margin international turnkey projects.

High Performance Trading with SAHI.